These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
255 related articles for article (PubMed ID: 19736431)
1. Cutaneous metastases from carcinoma breast: the common and the rare. Prabhu S; Pai SB; Handattu S; Kudur MH; Vasanth V Indian J Dermatol Venereol Leprol; 2009; 75(5):499-502. PubMed ID: 19736431 [TBL] [Abstract][Full Text] [Related]
2. [Tubular carcinoma of the breast (clinico-morphological characteristics)]. Frank GA; Volchenko NN Vopr Onkol; 1985; 31(5):15-21. PubMed ID: 2990106 [TBL] [Abstract][Full Text] [Related]
3. Follow-up care of patients with breast cancer. Tolaney SM; Winer EP Breast; 2007 Dec; 16 Suppl 2():S45-50. PubMed ID: 17697780 [TBL] [Abstract][Full Text] [Related]
4. The significance of intraduct appearances in breast cancer. Cowen PN; Bates C Clin Oncol; 1984 Mar; 10(1):67-72. PubMed ID: 6323084 [TBL] [Abstract][Full Text] [Related]
5. Recognizing malignant skin changes following breast cancer. Pakula AS; Robinson JK Am Fam Physician; 1992 Mar; 45(3):1287-92. PubMed ID: 1311898 [TBL] [Abstract][Full Text] [Related]
6. [Non-infiltrating intraductal carcinoma of the breast (author's transl)]. Contesso G; Petit JY Bull Cancer; 1979; 66(1):1-8. PubMed ID: 217470 [TBL] [Abstract][Full Text] [Related]
8. Integrative tumor board: recurrent breast cancer or new primary? Naturopathic medicine. Fulop JA Integr Cancer Ther; 2003 Sep; 2(3):276-83. PubMed ID: 15035892 [No Abstract] [Full Text] [Related]
9. Cytological criteria for the diagnosis of intraductal hyperplasia, ductal carcinoma in situ, and invasive carcinoma of the breast. Bofin AM; Lydersen S; Hagmar BM Diagn Cytopathol; 2004 Oct; 31(4):207-15. PubMed ID: 15452908 [TBL] [Abstract][Full Text] [Related]
10. [Cutaneous forms of breast cancer: Paget's disease and erysipeloid carcinoma]. Laugier P; Reiffers J Rev Med Suisse Romande; 1972 Apr; 92(4):245-54. PubMed ID: 4338653 [No Abstract] [Full Text] [Related]
11. [Immunohistochemical evidence of vimentin in fibrocystic breast disease and mammary carcinoma]. Alexiev B; Valkov I; Popov A Zentralbl Pathol; 1992 Sep; 138(4):284-8. PubMed ID: 1329942 [TBL] [Abstract][Full Text] [Related]
12. Cystic hypersecretory carcinoma: rare and poorly recognized variant of intraductal carcinoma of the breast. Report of five cases. Skalova A; Ryska A; Kajo K; Di Palma S; Kinkor Z; Michal M Histopathology; 2005 Jan; 46(1):43-9. PubMed ID: 15656885 [TBL] [Abstract][Full Text] [Related]
13. Gastro-intestinal metastases as first clinical manifestation of the dissemination of a breast cancer. Clavien PA; Laffer U; Torhost J; Harder F Eur J Surg Oncol; 1990 Apr; 16(2):121-6. PubMed ID: 2157608 [TBL] [Abstract][Full Text] [Related]
14. [Pigmented Paget's disease and pigmented breast cancer metastasis. Clinical and histologic simulation of malignant melanoma of the breast]. Kutzner H; Hügel H; Embacher G Hautarzt; 1992 Jan; 43(1):28-31. PubMed ID: 1319418 [TBL] [Abstract][Full Text] [Related]
15. Integrative tumor board: recurrent breast cancer or new primary? Radiation oncology. Hirsch A Integr Cancer Ther; 2003 Sep; 2(3):272-6. PubMed ID: 15035891 [No Abstract] [Full Text] [Related]
16. Mammographically detected, clinically occult ductal carcinoma in situ treated with breast-conserving surgery and definitive breast irradiation. Solin LJ; McCormick B; Recht A; Haffty BG; Taylor ME; Kuske RR; Bornstein BA; McNeese M; Schultz DJ; Fowble BL; Barrett W; Yeh IT; Kurtz JM; Amalric R; Fourquet A Cancer J Sci Am; 1996; 2(3):158-65. PubMed ID: 9166516 [TBL] [Abstract][Full Text] [Related]
17. Integrative tumor board: recurrent breast cancer or new primary? Medical oncology. Boyd DB Integr Cancer Ther; 2003 Sep; 2(3):270-2. PubMed ID: 15035890 [No Abstract] [Full Text] [Related]
18. Integrative tumor board: recurrent breast cancer or new primary? Case Presentation. Schmaltz J Integr Cancer Ther; 2003 Sep; 2(3):268-70. PubMed ID: 15035889 [No Abstract] [Full Text] [Related]
19. [Mistakes in the diagnosis of breast cancer]. Lunga II Khirurgiia (Mosk); 1984 Jun; (6):72-4. PubMed ID: 6087017 [No Abstract] [Full Text] [Related]
20. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. Mazouni C; Peintinger F; Wan-Kau S; Andre F; Gonzalez-Angulo AM; Symmans WF; Meric-Bernstam F; Valero V; Hortobagyi GN; Pusztai L J Clin Oncol; 2007 Jul; 25(19):2650-5. PubMed ID: 17602071 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]